{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:21:24Z","timestamp":1789676484208,"version":"4.0.1"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T00:00:00Z","timestamp":1476748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T00:00:00Z","timestamp":1476748800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute kidney injury (AKI) is a frequent complication of multiple myeloma and is associated with increased short-term mortality. Additionally, even a single episode of AKI can eventually lead to end-stage renal disease (ESRD), significantly reducing quality of life and long-term survival. In the setting of multiple myeloma, severe AKI (requiring dialysis) is typically secondary to cast nephropathy (CN). Renal injury in CN is due to intratubular obstruction from precipitation of monoclonal serum free light chains (sFLC) as well as direct tubular toxicity of sFLC via stimulation of nuclear factor (NF)\u03baB inflammatory pathways. Current mainstays of CN treatment are early removal of precipitating factors such as nephrotoxic drugs, acidosis and dehydration, together with rapid reduction of sFLC levels. Introduction of the proteasome inhibitor bortezomib has significantly improved the response rates in multiple myeloma due to its ability to rapidly reduce sFLC levels and has been referred to as \u201crenoprotective\u201d therapy. As an adjunct to chemotherapy, several new extracorporeal techniques have raised interest as a further means to reduce sFLC concentrations in the treatment of CN. Whether addition of extracorporeal therapies to renoprotective therapy can result in better renal recovery is still a matter of debate and there are currently no guidelines in this field. In this positon paper, we offer an overview of the available data and the authors\u2019 perspectives on extracorporeal treatments in CN.<\/jats:p>","DOI":"10.1007\/s40620-016-0347-9","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T11:00:14Z","timestamp":1476788414000},"page":"735-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology"],"prefix":"10.1093","volume":"29","author":[{"given":"P.","family":"Fabbrini","sequence":"first","affiliation":[{"name":"Clinica Nefrologica, ASST Monza San Gerardo Hospital, University Milano-Bicocca, Osp San Gerardo, via Pergolesi 33, 20851, Milan, Monza, Italy 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Finkel","sequence":"additional","affiliation":[{"name":"UT Health Science Center, University of Texas, 6410 Fannin St., Ste. 606, 77030, Houston, TX, USA 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gallieni","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biomedical Sciences, Nephrology and Dialysis Unit, San Carlo Borromeo Hospital, University of Milan, Milan, Italy 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Capasso","sequence":"additional","affiliation":[{"name":"Chair of Nephrology, Department of Cardio-Vascular Medicine, Second University of Naples, Naples, Italy 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cavo","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Hematology\/Oncology, Policlinico Sant\u2019Orsola, Bologna, Italy 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Santoro","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis, and Hypertension Unit, Sant\u2019Orsola-Malpighi University Hospital, Bologna, Italy 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pasquali","sequence":"additional","affiliation":[{"name":"U.O.C Nephrology and Dialysis, S. Maria Nuova Hospital, Reggio Emilia, Italy 7"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,10,18]]},"reference":[{"key":"2026012103464621300_CR1","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026012103464621300_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1586\/ehm.11.72","article-title":"Management of myeloma-associated renal dysfunction in the era of novel therapies","volume":"5","author":"Gaballa","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"2026012103464621300_CR3","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1158\/1078-0432.CCR-11-0498","article-title":"Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment","volume":"18","author":"Chanan-Khan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026012103464621300_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrneph.2011.168","article-title":"The pathogenesis and diagnosis of acute kidney injury in multiple myeloma","volume":"8","author":"Hutchison","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"2026012103464621300_CR5","first-page":"207","article-title":"Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival","volume":"56","author":"Abbott","year":"2001","journal-title":"Clin Nephrol"},{"issue":"7","key":"2026012103464621300_CR6","doi-asserted-by":"publisher","first-page":"e101819","DOI":"10.1371\/journal.pone.0101819","article-title":"The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment","volume":"9","author":"Uttervall","year":"2014","journal-title":"PLoS One"},{"key":"2026012103464621300_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ejim.2014.06.023","article-title":"Severe acute kidney injury and multiple myeloma: evaluation of kidney and patient prognostic factors","volume":"25","author":"Rodrigues","year":"2014","journal-title":"Eur J Intern Med"},{"key":"2026012103464621300_CR8","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/ndt\/gfp679","article-title":"Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA registry study","volume":"25","author":"Tsakiris","year":"2010","journal-title":"Nephrol Dial Trasplant"},{"issue":"5","key":"2026012103464621300_CR9","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1681\/ASN.2014090876","article-title":"End stage renal disease due to multiple myeloma in the United States, 2001\u20132010","volume":"27","author":"Reule","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2026012103464621300_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0009-8981(67)90036-8","article-title":"Effect of impaired hepatic and renal function on Bence Jones protein catabolism in human subjects","volume":"18","author":"Miettinen","year":"1967","journal-title":"Clin Chim Acta"},{"key":"2026012103464621300_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1084\/jem.126.2.207","article-title":"The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments","volume":"126","author":"Wochner","year":"1967","journal-title":"J Exp Med"},{"key":"2026012103464621300_CR12","first-page":"104","volume-title":"Serum Free light chain analysis","author":"Bradwell","year":"2006","edition":"4"},{"key":"2026012103464621300_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1136\/jcp.33.8.786","article-title":"Human alpha 1-microglobulin in various body fluids","volume":"33","author":"Takagi","year":"1980","journal-title":"J Clin Pathol"},{"key":"2026012103464621300_CR14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1681\/ASN.2006080821","article-title":"Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies","volume":"18","author":"Hutchison","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2026012103464621300_CR15","first-page":"1","article-title":"Treatment of acute kidney injury with cast nephropathy","volume":"82","author":"Walther","year":"2014","journal-title":"Clin Nephrol"},{"key":"2026012103464621300_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","article-title":"Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents","volume":"25","author":"Dimopoulos","year":"2014","journal-title":"Ann Oncol"},{"key":"2026012103464621300_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/leu.2012.182","article-title":"The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Leukemia"},{"key":"2026012103464621300_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ki.2015.201","article-title":"Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease","volume":"88","author":"Cohen","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"2026012103464621300_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1124\/jpet.108.142604","article-title":"Bortezomib-induced survival signals and genes in human proximal tubular cells","volume":"327","author":"Sark\u00f6zi","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"2026012103464621300_CR20","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma: initial clinical experience in patients with impaired renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"2026012103464621300_CR21","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"2026012103464621300_CR22","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026012103464621300_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3324\/haematol.2013.087585","article-title":"Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-hd4 trial","volume":"99","author":"Scheid","year":"2014","journal-title":"Haematologica"},{"key":"2026012103464621300_CR24","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026012103464621300_CR25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"2026012103464621300_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ki.2015.134","article-title":"Monoclonal gammopathy of renal significance: systemic involvement by benign condition","volume":"88","author":"L\u2019Imperio","year":"2015","journal-title":"Kidney Int"},{"issue":"4","key":"2026012103464621300_CR27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin Chem"},{"issue":"12","key":"2026012103464621300_CR28","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2215\/CJN.11161111","article-title":"Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases","volume":"7","author":"Leung","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2026012103464621300_CR29","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","article-title":"Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies","volume":"59","author":"Nasr","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"2026012103464621300_CR30","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.2215\/CJN.00650110","article-title":"The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies","volume":"5","author":"Fish","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2026012103464621300_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ndt\/gfv283","article-title":"Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients","volume":"31","author":"Ecoti\u00e8re","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2026012103464621300_CR32","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1136\/jcp.2010.079236","article-title":"Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney","volume":"63","author":"Basnayake","year":"2010","journal-title":"J Clin Pathol"},{"issue":"11","key":"2026012103464621300_CR33","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/ki.2008.108","article-title":"Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains","volume":"73","author":"Leung","year":"2008","journal-title":"Kidney Int"},{"key":"2026012103464621300_CR34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/ajh.24035","article-title":"Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment","volume":"90","author":"Zannetti","year":"2015","journal-title":"Am J Hematol"},{"issue":"10","key":"2026012103464621300_CR35","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1093\/ndt\/gfr773","article-title":"Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis","volume":"27","author":"Hutchison","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026012103464621300_CR36","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","article-title":"Review on uremic toxins: classification, concentration, and interindividual variability","volume":"63","author":"Vanholder","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"2026012103464621300_CR37","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ndt\/17.5.879","article-title":"Effect of dialysis on serum\/plasma levels of free immunoglobulin light chains in end-stage renal disease patients","volume":"17","author":"Cohen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2026012103464621300_CR38","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/ki.1988.127","article-title":"Controlled plasma exchange trial in acute renal failure due to multiple myeloma","volume":"33","author":"Zucchelli","year":"1988","journal-title":"Kidney Int"},{"issue":"4","key":"2026012103464621300_CR39","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1990.00390160111022","article-title":"Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy","volume":"150","author":"Johnson","year":"1990","journal-title":"Arch Intern Med"},{"issue":"11","key":"2026012103464621300_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"issue":"4","key":"2026012103464621300_CR41","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/ndt\/gfl628","article-title":"Plasma exchange in the treatment of acute renal failure of myeloma","volume":"22","author":"Movilli","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"24","key":"2026012103464621300_CR42","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1056\/NEJMc1101834","article-title":"Renal improvement in myeloma with bortezomib plus plasma exchange","volume":"364","author":"Burnette","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2026012103464621300_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/MNH.0000000000000101","article-title":"Plasmapheresis in cast nephropathy: yes or no?","volume":"24","author":"Madore","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026012103464621300_CR44","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/ajh.23189","article-title":"High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy","volume":"87","author":"Sinisalo","year":"2012","journal-title":"Am J Hematol"},{"issue":"7","key":"2026012103464621300_CR45","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/nep.12267","article-title":"Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008\u20132012","volume":"19","author":"Tan","year":"2014","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"2026012103464621300_CR46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/1744-9987.12432","article-title":"Citrate extended high cut-off hemodiafiltration for renal recovery in patients with multiple myeloma","volume":"20","author":"Marn Pernat","year":"2016","journal-title":"Ther Apher Dial"},{"issue":"4","key":"2026012103464621300_CR47","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2215\/CJN.04590908","article-title":"Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis","volume":"4","author":"Hutchison","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2026012103464621300_CR48","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.nefro.2016.03.011","article-title":"Thirteen treated of acute renal failure secondary to multiple myeloma with high cut off filters","volume":"36","author":"Berni Wennekers","year":"2016","journal-title":"Nefrologia"},{"issue":"5","key":"2026012103464621300_CR49","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00277-011-1383-0","article-title":"Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury","volume":"91","author":"Heyne","year":"2012","journal-title":"Ann Hematol"},{"issue":"5","key":"2026012103464621300_CR50","doi-asserted-by":"publisher","first-page":"e0154993","DOI":"10.1371\/journal.pone.0154993","article-title":"Impact of high-cut-off dialysis on renal recovery in dialysis-dependent multiple myeloma patients: results from a case-control study","volume":"11","author":"Gerth","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"2026012103464621300_CR51","doi-asserted-by":"publisher","first-page":"e0140463","DOI":"10.1371\/journal.pone.0140463","article-title":"Effectiveness of haemodiafiltration with heat sterilized high-flux polyphenylene HF dialyzer in reducing free light chains in patients with myeloma cast nephropathy","volume":"10","author":"Rousseau-Gagnon","year":"2015","journal-title":"PLoS One"},{"key":"2026012103464621300_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1745-6215-9-55","article-title":"European trial of free light chain removal byextended haemodialysis in cast nephropathy (EuLITE): a randomised control trial","volume":"9","author":"Hutchison","year":"2008","journal-title":"Trials"},{"key":"2026012103464621300_CR53"},{"key":"2026012103464621300_CR54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000316684","article-title":"Reduction of free immunoglobulin light chains using adsorption properties of hemodiafiltration with endogenous reinfusion","volume":"30","author":"Testa","year":"2010","journal-title":"Blood Purif"},{"issue":"2","key":"2026012103464621300_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40620-014-0130-8","article-title":"A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR)","volume":"28","author":"Pasquali","year":"2015","journal-title":"J Nephrol"},{"issue":"6","key":"2026012103464621300_CR56","first-page":"788","article-title":"Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure","volume":"33","author":"Pend\u00f3n-Ruiz de Mier","year":"2013","journal-title":"Nefrologia"},{"issue":"Suppl 2","key":"2026012103464621300_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000350849","article-title":"Polymethylmethacrylate membrane and serum free light chain removal: enhancing adsorption properties","volume":"35","author":"Fabbrini","year":"2013","journal-title":"Blood Purif"},{"issue":"2","key":"2026012103464621300_CR58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000350837","article-title":"The double polymethylmethacrylate filter (DELETE system) in the removal of light chains in chronic dialysis patients with multiple myeloma","volume":"35","author":"Santoro","year":"2013","journal-title":"Blood Purif"},{"key":"2026012103464621300_CR59"},{"key":"2026012103464621300_CR60"},{"key":"2026012103464621300_CR61","first-page":"S89","article-title":"Studio cinetico di rimozione delle catene leggere: confronto fra plasmaferesi tradizionale, plasmaferesi a cascata con resine adsorbenti, emodialisi mediante una membrana ad alto cut-off","volume":"S-47","author":"Pasquali","year":"2009","journal-title":"Giorn Ital Nefrol"},{"key":"2026012103464621300_CR62"},{"issue":"13","key":"2026012103464621300_CR63","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Meletios","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-016-0347-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-016-0347-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/29\/6\/735\/66030646\/joneph_29_6_347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-016-0347-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/29\/6\/735\/66030646\/joneph_29_6_347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:46:53Z","timestamp":1768985213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/29\/6\/735\/8371296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,18]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,10,18]]},"published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.1007\/s40620-016-0347-9","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,12,1]]},"published":{"date-parts":[[2016,10,18]]}}}